CHICAGO – August 21, 2018 – Paragon Biosciences (Paragon) today announced Skyline Biosciences (Skyline) as the newest addition to its growing portfolio of drug-development companies. Paragon identifies unmet patient needs, invests in the development of novel medicines, and incubates biopharmaceutical companies, such as Skyline.

“Skyline is working on promising therapies to treat oral precancerous lesions,” said Dr. Tim Cunniff, Executive Vice President of Research & Development at Paragon. “These therapies have the potential to extend a patient’s life by eliminating lesions before they have a chance to become malignant. There are currently no FDA-approved pharmacological treatments for this type of oral condition.”

In the U.S., there are well over 500,000 diagnosed cases of oral precancerous lesions. These lesions involve the epithelium of the mouth and are at risk for becoming an oral cancer. With no approved therapies for this condition, the current standard of care is limited to monitoring for progression to moderate or severe dysplasia. At that point, the only treatment is surgery, which is invasive and can be disfiguring.

“Paragon is incubating Skyline because of the critical need to develop new therapies for potentially life-threatening oral lesions,” said Jeff Aronin, Chairman and CEO of Paragon Biosciences. “Paragon’s mission is to accelerate biopharmaceutical innovations for severe medical conditions which do not yet have adequate treatments. Our investment in Skyline is another example of Paragon’s commitment to accelerating medical breakthroughs for patients in need.”

About Skyline Biosciences
Skyline Biosciences is developing first in-kind therapies to treat premalignant and malignant oral lesions. Skyline’s mission is to extend and improve quality of life for patients with oral oncology conditions. For more information visit:

About Paragon Biosciences
Paragon Biosciences, LLC improves the lives of patients suffering from debilitating diseases by building innovative biotechnology companies that bring important treatments to the market. Paragon’s portfolio companies are managed by healthcare industry leaders and biotech entrepreneurs committed to improving outcomes for patients. Paragon’s leadership and management team leverage their entrepreneurial experiences and their expertise to develop and finance biotechnology companies and accelerate their advancements. Paragon Biosciences is headquartered in Chicago, Illinois. For more information visit:

Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome
Jeff Aronin Named One of the 20 Most Influential Leaders in Healthcare for 2018